Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Halobetasol Propionate Foam in Adolescents with Plaque Psoriasis
NCT03992261Phase 4Completed
- Sponsor
- Mayne Pharma
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of Halobetasol propionate 0.05% lotion in plaque psoriasis, sponsored by Mayne Pharma. Primary endpoints: Number of Subjects to Exhibit Adrenal Suppression as Measured by a Cosyntropin Stimulation Test and Plasma Concentration of HBP at Day 15. Started Jun 2019; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotion
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03992261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992261.